GlassScriptPhysician profile
Gary D Wasserman
NPI 1518049832
$1,211.63
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $115 · 2021: $426 · 2022: $64.07 · 2023: $16.77 · 2024: $37.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $140.68 | 2019-2021 | |
| Medtronic USA, INC. | $96.12 | 2019 | |
| Pfizer INC. | $95.09 | 2019-2020 | |
| Axonics, INC. | $94.66 | 2021-2022 | |
| Bard Access Systems, INC. | $82.14 | 2019 | |
| Amgen INC. | $81.79 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.67 | 2020-2021 | |
| Myovant Sciences INC. | $54.38 | 2021 | |
| Allergan, INC. | $53.53 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $44.97 | 2020-2021 | |
| Urovant Sciences INC | $44.34 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $42.06 | 2019-2020 | |
| Clarus Therapeutics INC. | $30.00 | 2021 | |
| Janssen Biotech, INC. | $29.50 | 2019-2021 | |
| Bluewind Medical | $22.10 | 2024 | Revi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $20.42 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.51 | 2021 | |
| C. R. Bard Foundation, INC. | $18.22 | 2019 | |
| Dendreon Pharmaceuticals LLC | $17.45 | 2021 | |
| Procept Biorobotics Corporation | $16.93 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.77 | 2023 | Bard Urinary Drainage Bag |
| Boston Scientific Corporation | $15.24 | 2020 | |
| Abbvie INC. | $15.00 | 2019 | |
| Endo USA, INC. | $14.94 | 2024 | Xiaflex |
| Antares Pharma, INC. | $14.88 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.52 | 2021 | |
| Dentsply Ih INC. | $13.74 | 2021 | |
| Verity Pharmaceuticals INC. | $12.42 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.37 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $12.31 | 2019 | |
| Aytu Biopharma, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.